Since limited data are available on patients treated with immunochemotherapy [13], we showed that overexpression of survivin is in significant correlation with therapy response and the survival of patients with nodal DLBCL treated with immunochemotherapy. The gene discussed is BIRC5; the disease is diffuse large B-cell lymphoma.